This HTML5 document contains 52 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n18http://linked.opendata.cz/resource/mesh/concept/
n14http://linked.opendata.cz/resource/drugbank/drug/DB08801/identifier/kegg-drug/
n4http://linked.opendata.cz/resource/drugbank/drug/DB08801/identifier/drugbank/
n10http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n11http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n16http://linked.opendata.cz/resource/drugbank/drug/DB08801/identifier/chemspider/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n17http://linked.opendata.cz/ontology/mesh/
n5http://linked.opendata.cz/ontology/drugbank/
n6http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n13http://linked.opendata.cz/resource/drugbank/drug/DB08801/identifier/wikipedia/
n8http://linked.opendata.cz/resource/atc/
n15http://linked.opendata.cz/resource/drugbank/drug/DB08801/identifier/pharmgkb/
n7http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB08801
rdf:type
n5:Drug
n5:description
Dimetindene (Fenistil) is an antihistamine/anticholinergic used orally and locally as an antipruritic.
n5:generalReferences
# Lambrecht G, Gross J, Mutschler E: Neuronal soma-dendritic and prejunctional M1-M4 receptors in gastrointestinal and genitourinary smooth muscle. Life Sci. 1999;64(6-7):403-10. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10069503 # "Novartis Pamphlet":http://english.consumerhealth.eg.novartis.com/cms.php?id=products_fenistil
n5:group
approved
n5:indication
Indicated as symptomatic treatment of allergic reactions: urticaria, allergies of the upper respiratory tract such as hey fever and perennial rhinitis, food and drug allergies; pruritus of various origins, except pruritus due to cholestasis; insect bites. Dimethindene is also indicated for pruritus in eruptive skin diseases such as chicken-pox. Dimethindene can also be used as an adjuvant in eczema and other pruriginous dermatoses of allergic origin.
owl:sameAs
n10:DB08801 n11:DB08801
dcterms:title
Dimetindene
adms:identifier
n4:DB08801 n13:Dimetindene n14:D07853 n15:PA165958420 n16:20541
n5:mechanismOfAction
Dimethindene is a selective histamine H1 antagonist and binds to the histamine H1 receptor. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine.
n5:synonym
Dimethindene
n5:toxicity
As with other antihistaminic drugs, overdosage can produce the following symptoms: CNS depression accompanied by drowsiness (especially in adults), CNS stimulation and antimuscarinic effects (especially in children) including the following: excitation, ataxia, hallucinations, tonic or clonic spasms, mydriasis, dryness of the mouth, redness of the face, urine retention, fever and tachycardia. Blood hypotension is also possible. In its terminal phase, coma can be aggravated by cardiorespiratory colapse and death. There has been no report of a fatal outcome of Dimethindene overdosage.
n5:salt
n5:synthesisReference
Huebner, C.F.; U S . Patent 2,970,149; January 31, 1961; assigned to Ciba Pharmaceutical Products, Inc.
n17:hasConcept
n18:M0006449
n5:IUPAC-Name
n6:271B554F-363D-11E5-9242-09173F13E4C5
n5:InChI
n6:271B5555-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n6:271B5554-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n6:271B5551-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n6:271B5552-363D-11E5-9242-09173F13E4C5
n5:SMILES
n6:271B5553-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility
n6:271B554D-363D-11E5-9242-09173F13E4C5 n6:271B5565-363D-11E5-9242-09173F13E4C5
n5:logP
n6:271B554E-363D-11E5-9242-09173F13E4C5 n6:271B554B-363D-11E5-9242-09173F13E4C5
n5:logS
n6:271B554C-363D-11E5-9242-09173F13E4C5
n7:hasATCCode
n8:D04AA13 n8:R06AB03
n5:H-Bond-Acceptor-Count
n6:271B555B-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n6:271B555C-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n6:271B5556-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n6:271B5557-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n6:271B5559-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n6:271B5558-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n6:271B555A-363D-11E5-9242-09173F13E4C5
n5:affectedOrganism
Humans and other mammals
n5:casRegistryNumber
5636-83-9
n5:category
n5:Bioavailability
n6:271B5561-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n6:271B5563-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n6:271B5564-363D-11E5-9242-09173F13E4C5
n5:Melting-Point
n6:271B5566-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n6:271B5560-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n6:271B555F-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n6:271B5562-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n6:271B5550-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-acidic-
n6:271B555D-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n6:271B555E-363D-11E5-9242-09173F13E4C5